IGF1: Insulin-like growth factor 1
The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on IGF1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
| Dusigitumab | Phase 2 | MedImmune LLC | Antibody | InhibitorInsulin-like growth factor I inhibitor | 0 |
| Xentuzumab | Phase 2 | Boehringer Ingelheim Pharmaceuticals | Antibody | InhibitorInsulin-like growth factor I inhibitor | 0 |
- Growth delay due to insulin-like growth factor type 1 deficiency0.76
- Abnormality of the skeletal system0.40
- Microcephalic primordial dwarfism0.38
- Uterine corpus leiomyoma0.36
- Upper respiratory tract disorder0.31
- Refractive error0.30
- Preeclampsia0.29
- Nodular goiter0.29
- Endometriosis0.29
- COVID-190.28
- Tietze syndrome0.28
- Abnormality of refraction0.28
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3217394, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P05019, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets